Patients investigated for T-cell reactivity against 14 SCP1-derived peptides
. | HLA-DR configuration . | . | . | . | . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient . | B1* . | B1* . | B3* . | B4* . | B5* . | SCP1 expression in tumor . | Anti-SCP1 serum reactivity . | ||||
| 466 | 1501 | 1502 | NE | NE | 0101/0102 | + | - | ||||
| 468 | 0401 | 0701 | NE | 0101/0301 | NE | - | - | ||||
| 476 | 1110 | 1601 | 0202 | NE | 0202 | - | - | ||||
| 478 | 0404 | 1103 | 0202 | 0103 | NE | - | - | ||||
| 497 | 1401 | 1501 | 0202 | NE | 0101 | + | + | ||||
| 499 | 0701 | 1301 | 0202 | 0103 | NE | + | - | ||||
| 506 | 1104 | 1202 | 0202 | NE | NE | - | ND | ||||
. | HLA-DR configuration . | . | . | . | . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient . | B1* . | B1* . | B3* . | B4* . | B5* . | SCP1 expression in tumor . | Anti-SCP1 serum reactivity . | ||||
| 466 | 1501 | 1502 | NE | NE | 0101/0102 | + | - | ||||
| 468 | 0401 | 0701 | NE | 0101/0301 | NE | - | - | ||||
| 476 | 1110 | 1601 | 0202 | NE | 0202 | - | - | ||||
| 478 | 0404 | 1103 | 0202 | 0103 | NE | - | - | ||||
| 497 | 1401 | 1501 | 0202 | NE | 0101 | + | + | ||||
| 499 | 0701 | 1301 | 0202 | 0103 | NE | + | - | ||||
| 506 | 1104 | 1202 | 0202 | NE | NE | - | ND | ||||
NE indicates not expressed; ND, not determined.